In the future, subtype-based combination therapy trials, such as combination of other immune checkpoint blockades (LAG3 or TIGIT with PD-1) in IR type, TGF-β inhibition in MS type and anti-CD73 therapy in XB type will likely broaden the scope of application of immunotherapy strategies in OPC cancer patients. Here, PDCD1 is linked to myeloid sarcoma.